Toxicity management in thoracic chemoradioimmunotherapy: pirfenidone for low grade pneumonitis and lung fibrosis

Chinese Clinical Oncology · Published 2026-06-01 · DOI 10.21037/cco-2026-1-0019

Free full text

Authors (4)

Franz Zehentmayr, Elvis Ruznic, Raphaela Moosbrugger, Brane Grambozov

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Zehentmayr, F., Ruznic, E., Moosbrugger, R., et al. (2026). Toxicity management in thoracic chemoradioimmunotherapy: pirfenidone for low grade pneumonitis and lung fibrosis. Chinese Clinical Oncology. https://doi.org/10.21037/cco-2026-1-0019

Related articles

• Eribulin and trastuzumab in early-line HER2-positive metastatic breast cancer: evaluating an active chemotherapy partner in an evolving treatment landscape · Chinese Clinical Oncology · 2026 · Same journal
• Genome-wide 5-hydroxymethylcytosine in circulating cell-free DNA reflects DNA methylation dynamics for non-invasive detection of early hepatocellular carcinoma · Chinese Clinical Oncology · 2026 · Same journal
• Cadonilimab plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a step forward for bispecific immunotherapy? · Chinese Clinical Oncology · 2026 · Same journal
• Advancing the frontiers of hepatocellular carcinoma treatment: a comprehensive review of past, ongoing, and future clinical trials · Chinese Clinical Oncology · 2026 · Same journal
• First-line fulvestrant vs. anastrozole in hormone receptor-positive advanced breast cancer: insights from the final FALCON trial results · Chinese Clinical Oncology · 2026 · Same journal
• Protocol for the impact of medication therapy management on efficacy and safety of postoperative anticoagulation therapy in patients with colorectal cancer: an open-label, prospective and randomized clinical trial · Chinese Clinical Oncology · 2026 · Same journal
• Back to the future: “7+3” joins the venetoclax plus intensive chemotherapy movement · Chinese Clinical Oncology · 2026 · Same journal
• Temporal evolution of liver cancer etiology in China, 1990–2021: insights from the Global Burden of Disease Study 2021 · Chinese Clinical Oncology · 2025 · Same journal
• Fos-related antigen 1 is required for Helicobacter pylori-induced inflammatory response in gastric epithelial cells through NF-κB pathway · Chinese Clinical Oncology · 2026 · Same journal
• Drug-induced liver injury and acute pancreatitis during trastuzumab therapy in a BRCA1-mutated, HER2-positive breast cancer patient: a case report · Chinese Clinical Oncology · 2026 · Same journal